Immunome (IMNM) Change in Acquisitions & Divestments (2024 - 2025)
Immunome's (IMNM) quarterly Change in Acquisitions & Divestments came in at $125.0 million in Q3 2025, up 316.67% YoY from $30.0 million in Q3 2024, and up 108.33% on a QoQ basis from $60.0 million in Q2 2025.
Powered by 
Analysis
Immunome (IMNM) Change in Acquisitions & Divestments (2024 - 2025) Analysis & Trends
Immunome (IMNM) has 2 years of Change in Acquisitions & Divestments data on file, last reported at $125.0 million in Q3 2025.
- Quarterly Change in Acquisitions & Divestments rose 316.67% year-over-year to $125.0 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $185.0 million (changed N/A YoY) and the FY2025 annual result came in at $200.0 million, up 29.03% from the prior year.
- Change in Acquisitions & Divestments climbed to $125.0 million in Q3 2025, from $60.0 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $125.0 million in Q3 2025 to a low of $15.0 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immunome | 3.03 Bn | 2.51 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 125.00 Mn |
| Jun 30, 2025 | 60.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 85.00 Mn |
| Sep 30, 2024 | 30.00 Mn |